---
title: "Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/603392.SH.md"
symbol: "603392.SH"
name: "Beijing Wantai Biological Pharmacy Enterprise Co., Ltd."
industry: "Biotechnology"
datetime: "2026-05-21T01:33:08.905Z"
locales:
  - [en](https://longbridge.com/en/quote/603392.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/603392.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/603392.SH.md)
---

# Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392.SH)

## Company Overview

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, and sells biological diagnostic tests and vaccines in China and internationally. The company offers in vitro diagnostics and automated laboratory instruments, including Wan600, Wan BC2800, WanTLA immunoassay and biochemistry analyzers; chemiluminescence and biochemistry tests, including novel diagnostic tests for detection of Hepatitis virus infections; P-85 Ab for nasopharyngeal cancer screening; and TB-IGRA for large population screening. It also provides diagnostic assays, such as high-value Hepatitis B core antibody tests, Hepatitis E Urine tests, Hepatitis D virus detection, IL-6, HIV 4th generation CLIA, Helicobacter pylori antibody, gastrin-17, and soluble transferrin receptor assays; and enzyme-linked immunosorbent assay (ELISA), colloidal gold, molecular, clinical laboratory quality control products, and bioactive materials for various infectious diseases, such as HIV, Hepatitis, Tuberculosis, and Influenza A/B.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.ystwt.com](https://www.ystwt.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:11.000Z

**Overall: C (0.55)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 19 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 2.54% |  |
| Net Profit YoY | -437.68% |  |
| P/B Ratio | 4.19 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 49589025939.61 |  |
| Revenue | 1945140873.70 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -3.23% | D |
| Profit Margin | -20.01% | D |
| Gross Margin | 69.86% | A |
| Revenue YoY | 2.54% | C |
| Net Profit YoY | -437.68% | E |
| Total Assets YoY | -4.90% | D |
| Net Assets YoY | -3.27% | D |
| Cash Flow Margin | 14.50% | D |
| OCF YoY | 2.54% | C |
| Turnover | 0.14 | E |
| Gearing Ratio | 12.88% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "2.54%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-437.68%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.19",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "49589025939.61",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1945140873.70",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-3.23%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-20.01%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "69.86%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "2.54%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-437.68%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-4.90%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-3.27%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "14.50%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "2.54%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.14",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "12.88%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -124.30 | 74/81 | - | - | - |
| PB | 4.08 | 53/81 | 6.17 | 5.65 | 4.24 |
| PS (TTM) | 24.87 | 76/81 | 41.52 | 37.25 | 28.28 |
| Dividend Yield | 0.00% | - | 0.47% | 0.46% | 0.46% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-20T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Underweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 37.97 |
| Highest Target | 40.30 |
| Lowest Target | 40.30 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/603392.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/603392.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/603392.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/603392.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**